ClinVar Genomic variation as it relates to human health
NM_000041.3(APOE):c.[388T>C;478C>T]
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
NM_000041.3(APOE):c.[388T>C;478C>T]
- Other names
- APOE, APOE3, CYS112ARG AND ARG142CYS
- Functional consequence
- -
- Links
- ClinGen: CA041161
- OMIM: 107741.0008
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
APOE | - | - |
GRCh38 GRCh37 |
175 | 195 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (1) |
no assertion criteria provided
|
Feb 14, 2017 | RCV000019438.39 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Feb 14, 2017)
|
no assertion criteria provided
Method: literature only
|
HYPERLIPOPROTEINEMIA, TYPE III, AUTOSOMAL DOMINANT
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000039727.2
First in ClinVar: Apr 04, 2013 Last updated: Feb 17, 2017 |
Comment on evidence:
In a family reported by Havel et al. (1983), Rall et al. (1989) found that the members with type III hyperlipoproteinemia (617347) were compound heterozygotes … (more)
In a family reported by Havel et al. (1983), Rall et al. (1989) found that the members with type III hyperlipoproteinemia (617347) were compound heterozygotes for 2 different APOE alleles, one coding for the normal APOE3 and one for a previously undescribed variant APOE3 with 2 changes: arginine replacing cysteine at residue 112 and cysteine replacing arginine at residue 142. The variant APOE3 was defective in its ability to bind to lipoprotein receptors, a functional defect probably contributing to expression of type III HLP in this kindred. Type III HLP typically is associated with homozygosity for apolipoprotein E2 (arg158-to-cys); see 107741.0001. Dominant expression of type III HLP associated with apoE phenotype E3/3 is caused by heterozygosity for a common apoE variant, apoE3 (cys112-to-arg; arg142-to-cys). To determine the functional characteristics of the variant protein, Horie et al. (1992) used recombinant DNA techniques to produce the variant in bacteria. They also produced a non-naturally occurring variant, apoE(arg142cys), that had only the cysteine substituted at residue 142. They demonstrated that the cys142 variant was responsible for the defective binding to lipoprotein receptors because both showed the same defect. The arg112,cys142 variant predominates 3:1 over normal apoE3 in the very low density lipoproteins of plasma from an affected subject. Horie et al. (1992) concluded that unique properties of the arg112,cys142 variant provided an explanation for its association with dominant expression of type III HLP. (less)
|
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. | Montagne A | Nature | 2020 | PMID: 32376954 |
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. | Ruskey JA | European journal of medical genetics | 2019 | PMID: 29842932 |
Differential burden of rare protein truncating variants in Alzheimer's disease patients compared to centenarians. | Freudenberg-Hua Y | Human molecular genetics | 2016 | PMID: 27260402 |
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. | Reitz C | JAMA | 2013 | PMID: 23571587 |
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. | Liu CC | Nature reviews. Neurology | 2013 | PMID: 23296339 |
APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. | Youmans KL | The Journal of biological chemistry | 2012 | PMID: 23060451 |
Association between apolipoprotein E gene polymorphism and the risk of vascular dementia: a meta-analysis. | Yin YW | Neuroscience letters | 2012 | PMID: 22381401 |
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. | Choi JH | Molecular genetics and metabolism | 2011 | PMID: 21742527 |
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Sidransky E | The New England journal of medicine | 2009 | PMID: 19846850 |
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. | Caselli RJ | The New England journal of medicine | 2009 | PMID: 19605830 |
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. | Nichols WC | Neurology | 2009 | PMID: 18987351 |
Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. | Fairley C | Journal of inherited metabolic disease | 2008 | PMID: 18979180 |
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). | Hruska KS | Human mutation | 2008 | PMID: 18338393 |
APOE genotype and cognitive decline in a middle-aged cohort. | Blair CK | Neurology | 2005 | PMID: 15668424 |
Impact of APOE in mild cognitive impairment. | Farlow MR | Neurology | 2004 | PMID: 15557508 |
APOE-epsilon4 predicts dementia but not other psychiatric disorders after traumatic brain injury. | Koponen S | Neurology | 2004 | PMID: 15326261 |
Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. | Caselli RJ | Neurology | 2004 | PMID: 15184602 |
Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: Pathogenic changes and "modifier" polymorphisms. | Montfort M | Human mutation | 2004 | PMID: 15146461 |
Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. | Enzinger C | Annals of neurology | 2004 | PMID: 15048896 |
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. | DeMattos RB | Neuron | 2004 | PMID: 14741101 |
APOE genotype influences acquisition and recall following traumatic brain injury. | Crawford FC | Neurology | 2002 | PMID: 11940706 |
Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. | Liberman JN | Neurology | 2002 | PMID: 11940689 |
Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. | Mori E | Annals of neurology | 2002 | PMID: 11835377 |
Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. | Buttini M | Neuroscience | 2000 | PMID: 10799751 |
Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. | Friedman G | Neurology | 1999 | PMID: 9932938 |
Association of apolipoprotein E polymorphism with outcome after head injury. | Teasdale GM | Lancet (London, England) | 1997 | PMID: 10213549 |
Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. | Farrer LA | JAMA | 1997 | PMID: 9343467 |
Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. | Tang MX | American journal of human genetics | 1996 | PMID: 8644717 |
Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. | Myers RH | Neurology | 1996 | PMID: 8618665 |
Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. | Grace ME | The Journal of biological chemistry | 1994 | PMID: 8294487 |
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. | Saunders AM | Neurology | 1993 | PMID: 8350998 |
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. | Corder EH | Science (New York, N.Y.) | 1993 | PMID: 8346443 |
The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. | Horie Y | The Journal of biological chemistry | 1992 | PMID: 1730728 |
Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. | Rall SC Jr | The Journal of clinical investigation | 1989 | PMID: 2539388 |
Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. | Tsuji S | Proceedings of the National Academy of Sciences of the United States of America | 1988 | PMID: 3353383 |
Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. | Das HK | The Journal of biological chemistry | 1985 | PMID: 3922972 |
Nucleotide sequence and structure of the human apolipoprotein E gene. | Paik YK | Proceedings of the National Academy of Sciences of the United States of America | 1985 | PMID: 2987927 |
Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. | Havel RJ | The Journal of clinical investigation | 1983 | PMID: 6860421 |
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. | Weisgraber KH | The Journal of biological chemistry | 1981 | PMID: 7263700 |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=APOE | - | - | - | - |
click to load more click to collapse |
Text-mined citations for this variant ...
HelpRecord last updated May 27, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.